Merck KGaA, Pfizer's Bavencio set to seal bladder cancer approval after confirmatory trial scores

Bavencio could use the win.

More than two years after its makers — Germany’s Merck KGaA and Pfizer — secured FDA approval for a form of bladder cancer, the companies unveiled that the confirmatory study testing the PD-L1 inhibitor had performed as expected, helping patients live longer as a maintenance treatment versus standard-of-care.